Lilly Halts One Trial of Muscle-Sparing Drug With Zepbound (3)

Eli Lilly & Co. halted a study of an experimental drug designed to prevent obesity patients from losing too much muscle, citing strategic business reasons it didn’t disclose.

Lilly closed the trial on June 10, less than a month after it had started, according to a US registry of clinical trials that was updated late Wednesday. A similar study in obesity patients without diabetes remains active, according to the website.

The experimental shot is a cornerstone of the US drugmaker’s strategy for addressing the muscle loss common in patients who shed weight quickly. Others, including Roche Holding AG, Regeneron ...